Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anileridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.69 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.69 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anileridine SCHEMBL119086 | 1.00 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL27722317 | 0.99 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL26333 | 0.99 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL1237724 | 0.95 | KCNA3 (0.69) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Pheneridine SCHEMBL1922392 | 0.91 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL8741179 | 0.90 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Phenoperidine SCHEMBL28832646 | 0.90 | KCNA3 (0.67) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.84 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.82 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL11603600 | 0.82 | OPRM1 (0.79) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| CN-101663028-A | Combined effect of topiramate and ondansetron on alcohol consumption | UNIV VIRGINIA | 2010-03-03 | — | — | CN | disclosed |
| CN-101646676-A | 7,8-is saturated-4, (S)-N-steric isomer of 5-epoxy-morphinanium analogs | PROGENICS PHARM INC US | 2010-02-10 | — | — | CN | disclosed |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| US-4070494-A | Enteral pharmaceutical compositions | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | OPRL1, OPRK1, ACHE | OPRM1 8/4885OPRK1 2/4885KCNA3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.